
Opinion|Videos|July 16, 2026
Navigating Dosing Frequency With Revumenib and Ziftomenib
Compare revimumab and ziftomib dosing, food rules, tablet crushing, PPI interactions and half-life—key counseling tips to boost patient adherence.
Advertisement
Episodes in this series

In this episode, Ali discusses the clinical implications of twice-daily versus once-daily dosing in patients with relapsed/refractory AML who are frequently monitored in clinic. He explains how half-life differences impact differentiation syndrome management, toxicity offset, and practical adherence counseling.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Building the pharmacy of the future — trust, loyalty, and growth
2
Beyond the Transplant Center: IV Therapy in the Community
3
Understanding Axatilimab's Mechanism in the Context of Multiple Lines of Therapy
4
Incorporating Patient-Reported Symptoms into Treatment Plans
5






























































































